Silicosis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Silicosis is an irreversible condition with currently no cure. | Silicosis is an irreversible condition with currently no cure. Treatment options currently focus on alleviating the symptoms and preventing complications. | ||
==Medical Therapy== | ==Medical Therapy== | ||
* Patients with an evidence of silicosis on chest x-ray should avoid further exposure to silica | * Patients with an evidence of silicosis on chest x-ray should avoid further exposure to silica | ||
===Supportive therapy=== | ===Supportive therapy=== | ||
*Smoking cessation | *Smoking cessation | ||
* [[Bronchodilator]]s to facilitate breathing if airflow limitation present on spirometry. | *[[Bronchodilator]]s to facilitate breathing if airflow limitation present on spirometry. | ||
*Vaccination against influenza and pneumococcus | *Vaccination against influenza and pneumococcus | ||
*Supplemental oxygen (if indicated) to prevent complications of chronic hypoxemia | *Supplemental oxygen (if indicated) to prevent complications of chronic hypoxemia | ||
| Line 18: | Line 18: | ||
Tamoxifen citrate has been used for the treatment of breast cancer for its selective estrogen receptor modulator action. It also inhibits the production of transforming growth factor-beta (TGF-b) and insulin-like growth factor [2,3]. TGF-b has important roles in the formation of fibrosis such as the modulation of inflammation, wound repair, and immunity by decreasing lymphocyte proliferation and encouraging growth of fibroblasts [4]. These effects have been studied in postoperative adhesions [5], keloid fibroblast proliferation, and reducing collagen production [6,7]. In this study, we aimed to investigate possible effects of tamoxifen on progression, prevention, and treatment of the fibrotic pulmonary silicosis disease considering the anti-fibrotic effect shown in aforementioned studies<ref name="pmid25218282">{{cite journal| author=Yoldas O, Karaca T, Bilgin BC, Yilmaz OH, Simsek GG, Alici IO et al.| title=Tamoxifen citrate: a glimmer of hope for silicosis. | journal=J Surg Res | year= 2015 | volume= 193 | issue= 1 | pages= 429-34 | pmid=25218282 | doi=10.1016/j.jss.2014.08.013 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25218282 }} </ref> | Tamoxifen citrate has been used for the treatment of breast cancer for its selective estrogen receptor modulator action. It also inhibits the production of transforming growth factor-beta (TGF-b) and insulin-like growth factor [2,3]. TGF-b has important roles in the formation of fibrosis such as the modulation of inflammation, wound repair, and immunity by decreasing lymphocyte proliferation and encouraging growth of fibroblasts [4]. These effects have been studied in postoperative adhesions [5], keloid fibroblast proliferation, and reducing collagen production [6,7]. In this study, we aimed to investigate possible effects of tamoxifen on progression, prevention, and treatment of the fibrotic pulmonary silicosis disease considering the anti-fibrotic effect shown in aforementioned studies<ref name="pmid25218282">{{cite journal| author=Yoldas O, Karaca T, Bilgin BC, Yilmaz OH, Simsek GG, Alici IO et al.| title=Tamoxifen citrate: a glimmer of hope for silicosis. | journal=J Surg Res | year= 2015 | volume= 193 | issue= 1 | pages= 429-34 | pmid=25218282 | doi=10.1016/j.jss.2014.08.013 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25218282 }} </ref> | ||
Revision as of 19:19, 17 June 2015
|
Silicosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Silicosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Silicosis medical therapy |
|
Risk calculators and risk factors for Silicosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Silicosis is an irreversible condition with currently no cure. Treatment options currently focus on alleviating the symptoms and preventing complications.
Medical Therapy
- Patients with an evidence of silicosis on chest x-ray should avoid further exposure to silica
Supportive therapy
- Smoking cessation
- Bronchodilators to facilitate breathing if airflow limitation present on spirometry.
- Vaccination against influenza and pneumococcus
- Supplemental oxygen (if indicated) to prevent complications of chronic hypoxemia
Tamoxifen citrate has been used for the treatment of breast cancer for its selective estrogen receptor modulator action. It also inhibits the production of transforming growth factor-beta (TGF-b) and insulin-like growth factor [2,3]. TGF-b has important roles in the formation of fibrosis such as the modulation of inflammation, wound repair, and immunity by decreasing lymphocyte proliferation and encouraging growth of fibroblasts [4]. These effects have been studied in postoperative adhesions [5], keloid fibroblast proliferation, and reducing collagen production [6,7]. In this study, we aimed to investigate possible effects of tamoxifen on progression, prevention, and treatment of the fibrotic pulmonary silicosis disease considering the anti-fibrotic effect shown in aforementioned studies[1]
References
- ↑ Yoldas O, Karaca T, Bilgin BC, Yilmaz OH, Simsek GG, Alici IO; et al. (2015). "Tamoxifen citrate: a glimmer of hope for silicosis". J Surg Res. 193 (1): 429–34. doi:10.1016/j.jss.2014.08.013. PMID 25218282.